Mustang Bio Inc (MBIO)

$1.02 -0.01 (-0.97%)
Market Cap 4.51M
Revenue (ttm) 0.00
Net Income (ttm) -15.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 171,800
Avg Vol 495,764
Day's Range N/A - N/A
Shares Out 4.38M
Stochastic %K 6%
Beta 2.24
Analysts Strong Buy
Price Target $8.00

Company Profile

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 201...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
95 Sawyer Road, Suite 110, Waltham, United States
nonamestockz
nonamestockz Jun. 24 at 6:13 PM
$MBIO Next step 1.65
0 · Reply
SMM82
SMM82 Jun. 24 at 1:54 PM
$MBIO All time low on deck… last 10-Q was brutal, with no sign of significant developments. Fortress Bio company presentation doesn’t paint a rosier picture for MBIO either, years off from anything substantial if they can even stay afloat.
3 · Reply
wilosmiles
wilosmiles Jun. 23 at 9:20 PM
$MBIO price is down but rsi still not oversold
0 · Reply
Plain360
Plain360 Jun. 23 at 8:44 PM
$MBIO Have a small position will see where it goes, if it drops under .95 stop loss activated.
0 · Reply
SMM82
SMM82 Jun. 20 at 8:35 PM
$MBIO Lets see under $1 on monday!
0 · Reply
makedatbread88
makedatbread88 Jun. 20 at 12:36 PM
$MBIO random volume pre market something’s up
0 · Reply
nonamestockz
nonamestockz Jun. 18 at 8:13 PM
$MBIO something will come up soon - rising volume - new support - same like $AQB
1 · Reply
wilosmiles
wilosmiles Jun. 18 at 10:21 AM
$MBIO look at the length of the oversold period highlighted below. 10 weeks.
0 · Reply
wilosmiles
wilosmiles Jun. 17 at 9:38 PM
$MBIO rsi just crossed into oversold. could stay for a while, the longer it stays oversold the more explosive the reversal.
0 · Reply
nonamestockz
nonamestockz Jun. 17 at 8:22 PM
$MBIO pump will come anyway $CRKN $RGC $ENVB $ZBAI
0 · Reply
Latest News on MBIO
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mar 5, 2025, 4:15 PM EST - 4 months ago

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Feb 27, 2025, 4:05 PM EST - 4 months ago

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 11, 2025, 4:10 PM EST - 4 months ago

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering

Feb 10, 2025, 8:00 AM EST - 4 months ago

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering

Feb 6, 2025, 7:00 AM EST - 5 months ago

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Reverse Stock Split

Jan 14, 2025, 8:00 AM EST - 5 months ago

Mustang Bio Announces Reverse Stock Split

Mustang Bio Receives Positive Listing Determination from Nasdaq

Nov 12, 2024, 8:30 AM EST - 8 months ago

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Nov 7, 2024, 8:30 AM EST - 8 months ago

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Oct 24, 2024, 2:10 PM EDT - 8 months ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

ENVB

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 21, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Why are Mustang Bio shares (MBIO) up almost 500%?

Jun 18, 2024, 2:52 AM EDT - 1 year ago

Why are Mustang Bio shares (MBIO) up almost 500%?

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Jun 17, 2024, 9:21 AM EDT - 1 year ago

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Mustang Bio Announces Closing of $4 Million Public Offering

May 2, 2024, 4:01 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4 Million Public Offering

Mustang Bio Announces Pricing of $4 Million Public Offering

Apr 29, 2024, 8:00 PM EDT - 1 year ago

Mustang Bio Announces Pricing of $4 Million Public Offering

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mar 11, 2024, 4:05 PM EDT - 1 year ago

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Mar 7, 2024, 7:30 AM EST - 1 year ago

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 1 year ago

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Dec 11, 2023, 8:30 AM EST - 1 year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 14, 2023, 4:05 PM EST - 1 year ago

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:28 AM EDT - 1 year ago

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 30, 2023, 2:15 PM EDT - 1 year ago

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 12:30 PM EDT - 1 year ago

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Oct 26, 2023, 9:00 AM EDT - 1 year ago

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Sep 7, 2023, 8:15 AM EDT - 1 year ago

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Aug 16, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio to Participate in Two August 2023 Investor Conferences

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio to Participate in Two August 2023 Investor Conferences

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Jul 31, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 15, 2023, 4:01 PM EDT - 2 years ago

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

May 18, 2023, 8:03 AM EDT - 2 years ago

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 12, 2023, 4:05 PM EDT - 2 years ago

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

May 11, 2023, 4:03 PM EDT - 2 years ago

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 29, 2023, 4:15 PM EDT - 2 years ago

Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Jan 17, 2023, 8:15 AM EST - 2 years ago

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Dec 19, 2022, 8:30 AM EST - 2 years ago

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 14, 2022, 4:05 PM EST - 2 years ago

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Oct 27, 2022, 8:00 AM EDT - 2 years ago

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Oct 6, 2022, 8:30 AM EDT - 2 years ago

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Sep 23, 2022, 4:55 PM EDT - 3 years ago

Mustang Bio: This Horse May Gallop Still

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Jul 27, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

nonamestockz
nonamestockz Jun. 24 at 6:13 PM
$MBIO Next step 1.65
0 · Reply
SMM82
SMM82 Jun. 24 at 1:54 PM
$MBIO All time low on deck… last 10-Q was brutal, with no sign of significant developments. Fortress Bio company presentation doesn’t paint a rosier picture for MBIO either, years off from anything substantial if they can even stay afloat.
3 · Reply
wilosmiles
wilosmiles Jun. 23 at 9:20 PM
$MBIO price is down but rsi still not oversold
0 · Reply
Plain360
Plain360 Jun. 23 at 8:44 PM
$MBIO Have a small position will see where it goes, if it drops under .95 stop loss activated.
0 · Reply
SMM82
SMM82 Jun. 20 at 8:35 PM
$MBIO Lets see under $1 on monday!
0 · Reply
makedatbread88
makedatbread88 Jun. 20 at 12:36 PM
$MBIO random volume pre market something’s up
0 · Reply
nonamestockz
nonamestockz Jun. 18 at 8:13 PM
$MBIO something will come up soon - rising volume - new support - same like $AQB
1 · Reply
wilosmiles
wilosmiles Jun. 18 at 10:21 AM
$MBIO look at the length of the oversold period highlighted below. 10 weeks.
0 · Reply
wilosmiles
wilosmiles Jun. 17 at 9:38 PM
$MBIO rsi just crossed into oversold. could stay for a while, the longer it stays oversold the more explosive the reversal.
0 · Reply
nonamestockz
nonamestockz Jun. 17 at 8:22 PM
$MBIO pump will come anyway $CRKN $RGC $ENVB $ZBAI
0 · Reply
HeyHoser
HeyHoser Jun. 17 at 7:28 PM
$MBIO pile of shit
0 · Reply
wilosmiles
wilosmiles Jun. 17 at 6:32 PM
$MBIO never take advice from a never-seller, they hold thru delisting off the pinks.
0 · Reply
ka1954
ka1954 Jun. 17 at 6:00 PM
$MBIO no reason for this much selling last 3 days. stop selling people !!!
0 · Reply
nonamestockz
nonamestockz Jun. 17 at 2:26 PM
$MBIO rebound
0 · Reply
ka1954
ka1954 Jun. 17 at 2:17 PM
$MBIO selling for last 3 days, what the fuck
0 · Reply
nonamestockz
nonamestockz Jun. 17 at 6:39 AM
$ZBAI Next Runner with $MBIO
0 · Reply
wilosmiles
wilosmiles Jun. 16 at 10:18 PM
$MBIO rsi shows more downside likely
0 · Reply
nonamestockz
nonamestockz Jun. 16 at 5:35 PM
$MBIO what’s these 5k Orders? Only MM or Bots - no real trading - on watch
0 · Reply
69savage
69savage Jun. 16 at 4:36 PM
$MBIO @cheesedonkey what u think of it now my man
1 · Reply
wilosmiles
wilosmiles Jun. 16 at 2:04 PM
$MBIO reminder: just did a 1:50 r/s in january. will it hold $1? prolly not
2 · Reply
toni1965
toni1965 Jun. 16 at 7:28 AM
$MBIO Today is the day
0 · Reply
SMM82
SMM82 Jun. 13 at 10:28 PM
$MBIO Doing MBIO things
0 · Reply